Elysium announces epigenetic aging clinical trial

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

Elysium Health is to study correlations between epigenetic aging and amounts of NAD+ and other biomarkers in a new clinical trial.

Fresh on the back of closing their Series C with $40m from investors including Mayo Clinic Ventures and General Catalyst it appears that Elysium Health is wasting no time in pressing ahead with new trials.

Elysium‘s new clinical trial at Duke Clinical Research Institute is going to measure amounts of interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, patterns in DNA methylation and – most importantly – NAD+. By correlating this data with the biological and chronological age of trial participants, Elysium researchers hope to determine to what extent NAD+ levels and those of the other biomarkers are associated with biological age.

Elysium plans to use its next-generation epigenetic platform, Algorithmic Platform for Epigenetic Examination (APEX), to calculate biological age in this trial. APEX has refined biological age-measuring technology that now includes a proprietary measure that examines global methylation patterns and will, according to a press release “address the inherent variability of earlier epigenetic age predictors”. Elysium’s supporting data about the improved system will be released later this year.


“Having studied aging for more than 30 years, it’s my belief that the field is at a tipping point …”


 

NAD+, or nicotinamide adenine dinucleotide, is a vital coenzyme – a chemical that enzymes need in order to function. Found in every cell in the body, NAD+ plays two crucial roles in the human body: it assists  respiration, the process by which cells convert glucose and oxygen into energy, and helps proteins regulate cellular function. Sirtuins, the so-called “guardians of the genome” that regulate cellular homeostasis, keeping every single cell in balance, will only function in the presence of NAD+.

The rub is that levels of NAD+ decline with age. Science is keen to find out why this happens, whether the drop-off can be arrested or reversed and exactly what the implications are for aging.

Speaking about the new trial, Elysium Health chief scientist and director of the Glenn Center for Biology of Aging Research at MIT Dr Leonard Guarente said: “Over the past decade, epigenetic tests have evolved to measure biological age with an increasing level of accuracy.

“Having studied aging for more than 30 years, it’s my belief that the field is at a tipping point. The newfound ability to measure biological age allows us to study whether interventions can have an impact, thus unlocking the potential to realize the benefits of aging research in our lifetime [1].”

Biomarkers are hot news in the Longevity world. They are signature molecules that can signpost the presence and indicate the progression of cancer, disease or aging. We’ve also addressed the wider-world of biomarkers such as audio and cognitive and will expand further on this whole subject over coming weeks.

[1] https://prn.to/2Tc46se

Image credit: Elysium Health
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Genflow IPO “starts a new chapter” for longevity biotech

Company floats on London Stock Exchange and becomes Europe’s first publicly traded longevity biotech. Today, Genflow Biosciences became the first longevity biotech IPO of 2022...

    Subscribe to our newsletter